Pfizer.. Allergan Merge..$160 Billion Deal.. New Behemoth in the Drug World
What Does Pfizer Have to do with the World of Stem Cells?
Most people would not call Pfizer a stem cell company, much less a cell therapy company, a regenerative medicine company, or even a biotech company. Pfizer is viewed as a “classic and traditional” pharmaceutical company, best known for its blockbuster sales of drugs, such as Lipitor and Viagra. While Pfizer is largely a drug company, the company has expressed periodic interest in the stem cell sector.
Biotech giant Celgene reached a deal to acquire Juno Therapeutics for $9 billion and Seattle Genetics will pay $614 million to acquire Cascadian Therapeutics.
Global Stem Cells Group to Host Stem Cells and Regenerative ... ISSCA Physicians looking for new alternatives to improve the quality of life of their patients through emerging regenerative medicine protocols..
“We are pleased to be able to open the doors on a new Stem Cells Center in Europe,” noted Novas. “The GSCG is continually exploring opportunities to deliver new stem-cell based treatment options to patients across Europe, and the Valencia center gives us the opportunity to do this while meeting our strategic mission to expand our presence in Europe.”
In opening the new center, the GSCG has signed an agreement with Dra. Laura Maria Caicedo, medical director of the Instituto Valenciano MEDEC (https://medec.es/conoce-medec/#equipoMedico). Dr. Caicedo is a specialist on hair loss with an interest in delivering stem cell based treatments to her patients and others in Valencia.
CONSUMER REPORT..stem cells market. a whole lot of demand
https://consumerreportsreview.com/stem-cells-market-is-likely-to-exhibit-a-strong-13-80-cagr-between-2017-and-2025/ The innovative new center will provide training in regenerative medicine for doctors located in Belgium and France. ..We look forward to ISSCA’s exciting new partnership with Belgium’s Churchill Aesthetic Center and the possibilities it brings in delivering safe and effective regenerative medicine treatment options to more patients across the globe,” said Benito Novas, CEO of the Global Stem Cells Group.
Market Data 
Markets 
AI
